Conference Correspondent

Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor

Dr Hope Rugo discusses studies that are aiming to evaluate the effect that CDK4/6 inhibitors have on patients with HER2+ breast cancer. Read More ›

What Differentiates Abemaciclib, Ribociclib, and Palbociclib?

Hope S. Rugo, MD, describes how she would treat a patient with HER-positive metastatic breast cancer that has progressed with a CDK4/CDK6 inhibitor plus an aromatase inhibitor. Read More ›

Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer

Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer. Read More ›

A Phase 1b Study of Abemaciclib plus Pembrolizumab for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer

Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy. Read More ›

Phase 1-2 Trial of Pembrolizumab and Either Doxorubicin or an Aromatase Inhibitor for Triple-Negative or HR-Positive Metastatic Breast Cancer

The combination of abemaciclib plus pembrolizumab is safe and effective in women with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer. Read More ›

Abemaciclib for the Treatment of Brain Metastases Secondary to HR-Positive Breast Cancer

The combination of the PD-1 inhibitor pembrolizumab plus either doxorubicin or an aromatase inhibitor may be a feasible approach to treating triple-negative or hormone receptor (HR)-positive metastatic breast cancer. Read More ›

Phase 2 Study of the Feasibility and Safety of Radium-223 Dichloride plus Hormonal Therapy and Denosumab for the Treatment of HR-Positive Breast Cancer with Bone-Dominant Metastasis

Abemaciclib demonstrated efficacy and an acceptable safety profile in treating brain metastases in hormone receptor (HR)-positive/HER2-negative breast cancer, but was not effective for brain metastases in HR-positive/HER2-positive breast cancer. Read More ›

Efficacy and Safety of Abemaciclib in Patients with Liver Metastases in the MONARCH 1, 2, and 3 Studies

The addition of Ra-223 to hormonal therapy and denosumab is a feasible and safe combination therapy in patients with hormone receptor (HR)-positive breast cancer with bone-dominant metastasis. Read More ›